4T1細胞 
	
		數量:	大量
	
	
		生長狀態:	貼壁生長
	
	
		運輸方式:	凍存運輸
	
	
		細胞形態:	上皮樣
	
	
		是否是腫瘤細胞:	0
	
	
		物種來源:	小鼠
	
	
		器官來源:	乳腺
	
	
		ATCC Number:	CRL-2539?
	
	
		相關**:	腫瘤
	
	
		品系:	BALB/cfC3H
	
	
		Designations:	4T1
	
	
		Depositors:	 BA Pulaski
	
	
		4T1細胞Biosafety Level:	1
	
	
		Shipped:	frozen
	
	
		Medium & Serum:	See Propagation
	
	
		Growth Properties:	adherent
	
	
		Organism:	Mus musculus deposited as mouse
	
	
		Morphology:	epithelial
	
	
		
	
	
		Source:	Organ: mammary gland
	
	
		Strain: BALB/cfC3H
	
	
		Disease: tumor
	
	
		Permits/Forms:	In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
	
	
		Applications:	4T1-induced tumors can be used as a post-operative model as well as a non-surgical model because the 4T1-induced tumor metastasizes spontaneously in both models with similar kinetics.
	
	
		4T1細胞Because 4T1 is resistant to 6-thioquanine, micro-metastatic cells (as few as 1) can be detected in many distant site organs with better accuracy that most tumor models.
	
	
		When injected into BALB/c mice, 4T1 spontaneously produces highly metastatic tumors that can metastasize to the lung, liver, lymph nodes and brain while the primary tumor is growing in situ.
	
	
		Tumorigenic:	Yes
	
	
		Comments:	4T1 is a 6-thioguanine resistant cell line selected from the 410.4 tumor without mutagen treatment.
	
	
		When injected into BALB/c mice, 4T1 spontaneously produces highly metastatic tumors that can metastasize to the lung, liver, lymph nodes and brain while the primary tumor is growing in situ.
	
	
		The primary tumor does not have to be removed to induce metastatic growth.
	
	
		The tumor growth and metastatic spread of 4T1 cells in BALB/c mice very closely mimic human breast cancer. This tumor is an animal model for stage IV human breast cancer.
	
	
		4T1-induced tumors can be used as a post-operative model as well as a non-surgical model because the 4T1-induced tumor metastasizes spontaneously in both models with similar kinetics.
	
	
		Because 4T1 is resistant to 6-thioquanine, 4T1細胞micro-metastatic cells (as few as 1) can be detected in many distant site organs with better accuracy that most tumor models. There is no need to count nodules or weight target organs.
	
	
		Propagation:	ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
	
	
		Temperature: 37.0°C
	
	
		Atmosphere: air, 95%; carbon dioxide (CO2), 5%
	
	
		Subculturing:	Protocol: NOTE: the cells should not be allowed to become confluent, subculture at 80% of confluence. Remove medium, and rinse with 0.25% trypsin-0.53mM EDTA solution. Remove the solution and add an additional 1 to 2 ml of trypsin-EDTA solution. Allow the flask to sit at room temperature (or at 37.0°C) until the cells detach. Add fresh culture medium, aspirate and dispense into new culture flasks.
	
	
		Subcultivation Ratio: A subcultivation ratio of 1:6 to 1:8 is recommended
	
	
		Medium Renewal: Every 2 to 3 days
	
	
		Preservation:	Freeze medium: Complete growth medium 95%; DMSO, 5%
	
	
		Storage temperature: liquid nitrogen vapor temperature
	
	
		Related Products:	Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
	
	
		recommended serum:ATCC 30-2020
	
	
		References:	49687: Pulaski BA, et al. Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon gamma. Cancer Immunol. Immunother. 49: 34-45, 2000. PubMed: 10782864
	
	
		49688: 4T1細胞Pulaski BA, Ostrand-Rosenberg S. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res. 58: 1486-1493, 1998. PubMed: 9537252
	
	
		49689: Pulaski BA, et al. Cooperativity of Staphylococcal aureus enterotoxin B superantigen, major histocompatibility complex class II, and CD80 for immunotherapy of advanced spontaneous metastases in a clinically relevant postoperative mouse breast cancer model. Cancer Res. 60: 2710-2715, 2000. PubMed: 10825145
	
	
		49690: Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 52: 1399-1405, 1992. PubMed: 1540948